Skip to main content

Advertisement

Table 3 Subgroup analysis of HIV+TB (n = 63) against nevirapine trough concentrations at 28 days

From: The antiretroviral efficacy of highly active antiretroviral therapy and plasma nevirapine concentrations in HIV-TB co-infected Indian patients receiving rifampicin based antituberculosis treatment

S.N. Subgroups Number of cases Mean Nevirapine concentrations at day 28 (μg/ml/) Standard deviation P value
1 HIV+TB (Cases) 63 2.78 1.60 --
2a Cases alive at the end Of 48 weeks 49 2.80 1.53 0.85
2b Cases who died during the study period 13 2.70 1.92  
3a Cases with undetectable viral loads at the end of 24 weeks 28 3.08 1.76 0.19
3b Cases who died or had detectable viral loads at the end of 24 weeks 32 2.52 1.48  
4a Cases with undetectable viral load at the end of 24 weeks 28 3.08 1.76 0.14
4b Cases who were alive but had detectable Viral load at the end of 24 weeks 19 2.40 1.14